drugset / Trial / NCT05382377
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.
Timeline
- Start
- 2022-05-17
- Primary completion
- 2024-05-17
- Completion
- 2026-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belumosudil | Small molecule | — | — |